Business Wire

KANEKA: “Development of Polymer Synthesis Technology by Microorganisms using CO2 as Direct Raw Material” selected as a NEDO Green Innovation Fund Project”

31.3.2023 17:09:00 EEST | Business Wire | Press release

Share

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka; hereinafter "Kaneka"), Bacchus Bio innovation Co., Ltd (Headquarters: Kobe-city, Hyogo; President: Mikio Tanji; hereinafter "Bacchus"), JGC Holdings Corporation (Headquarters: Yokohama-city Kanagawa; Chairman and CEO: Masayuki Sato; hereinafter "JGC HD"), and Shimadzu Corporation (Headquarters: Kyoto-city, Kyoto; President: Yasunori Yamamoto; hereinafter "Shimadzu") have announced that the proposal of a joint project, “Development of Polymer Synthesis Technology by microorganisms using CO2 as direct raw material (hereinafter referred to as ‘the Project’)” had been selected by the "Green Innovation Fund Project*1 / Promotion of Carbon Recycling Using CO2 from Biomanufacturing Technology as a Direct Raw Material” as a planned implementation sponsored by the New Energy and Industrial Technology Development Organization (NEDO).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230331005155/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Figure 1) Recycling-oriented Biomanufacturing Technology (Graphic: Business Wire)

This project will contribute to the realization of carbon recycling in the "Green Growth Strategy Through Achieving Carbon Neutrality in 2050" formulated by the Ministry of Economy, Trade and Industry with related ministries and agencies on December 25, 2020 (revised on June 18, 2021). The goal of the project is to realize recycling-oriented biomanufacturing technology that does not depend on fossil resources by developing microorganisms that produce biodegradable polymers from CO2 and developing production process technology, combining the knowledge and technology that the four companies have cultivated over the years.

During the project period (FY2023 to FY2030), the following three themes will be addressed.

  • Establishment of a gas fermentation biofoundry*2 using CO2 as a raw material (Bacchus and Shimadzu)
  • Development and improvement of biopolymer-producing microorganisms (Kaneka)
  • Development and demonstration of production technology using microorganisms capable of producing substances from CO2 (Kaneka, JGC HD, Shimadzu)

[ Kaneka ] https://www.kaneka.co.jp/en/
Kaneka is the first company in the world to successfully commercialize KANEKA Biodegradable Polymer Green PlanetTM ("Green Planet"), which is produced by microorganisms from vegetable oil and other raw materials. In this project, based on the synthetic microbiology and polymer production, processing technologies it has cultivated to date, Kaneka will develop new microorganisms that produce Green Planet directly from CO2, and will also launch a semi-commercial plant to conduct production demonstration for Green Planet industrialization. In addition, we will lead this project as the managing company.

[ Bacchus ] https://www.b2i.co.jp/
Bacchus is a data-driven biofoundry company. Bacchus aims to drastically shorten the breeding time of smart cells*3 by upgrading the breeding platform consolidating its proprietary technologies. By utilizing its own digital technology, Bacchus will design cells optimized for gas fermentation and create a variety of species. In addition, they will introduce and utilize data from a high-throughput evaluation system jointly developed with Shimadzu, and aim to build an "Integrated Biofoundry*4" that will provide one-stop service from microbial breeding to process development with JGC HD.

[ JGC HD ] https://www.jgc.com/en/
JGC HD has a profound knowledge of the safe gas handling of gases including hydrogen gas and process scale-up cultivated through its EPC (Engineering, Procurement, and Construction) business in the oil and gas fields, as well as in optimized culture tank design technology in the life science field. In this project, JGC HD will develop and scale-up a safe handling system for mixed gases containing CO2, H2, and O2 and a highly efficient gas fermentation process in addition to establishing an “Integrated Biofoundry” with Bacchus which will provide a one-stop service from microbial breeding to process development.

[ Shimadzu ] https://www.shimadzu.com/
Shimadzu, with the aim of solving social issues, has accumulated a variety of know-how by providing analytical measurement and robotics technologies to a wide range of fields and data analysis technologies using AI-based systems. In this project, Shimadzu will work on the development of high-speed productivity evaluation technology, which is indispensable for the construction of a biofoundry. Shimadzu will also develop an evaluation system to measure gas fermentation in the semi-commercial plant which is to be constructed as part of the project and support safe and highly efficient fermentation.

*1. A project to support companies and others working on management issues toward Japan's "Carbon Neutrality in 2050," from R&D and demonstration to social implementation by FY2030. The program covers 14 fields: transportation/manufacturing-related industries including carbon recycling/materials industries, energy-related industries, and home/office-related industries.
*2. Biofoundry: Microorganism development platform that creates microorganisms with designed functions to efficiently produce useful substances
*3. Smart cell: A cell that is highly designed and has an enhanced ability to efficiently produce the desired substance
*4. Integrated Biofoundry: A one-stop biomanufacturing platform that provides everything from microbial breeding to process development

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

KANEKA CORPORATION
Investors & Public Relations Department
Chika Harada
Info_Pro@kaneka.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye